TotalMarketCap

Outlook Therapeutics

OTLKNasdaq United StatesHealth CareBiotechnology: Biological Products (No Diagnostic Substances)

Market cap

$107.287 M

$0.44 -4.63%

Close of 6 Nov 2026

As of 6 Nov 2026, Outlook Therapeutics (OTLK) has a market capitalization of $107.3M. Market cap measures the value of outstanding equity at market prices; company totals combine applicable share classes. Prices and market caps come from Nasdaq, with financial fundamentals from SEC filings. See sources and calculation details.

Revenue

$1.41M

#3426 by revenue

Earnings

-$62.4M

Loss-making

Shares outstanding

243,447,554

Latest filing cover page

P/E ratio

—

Cap ÷ net income

Biotechnology: Biological Products (No Diagnostic Substances), ranked by market cap

All 163 →
  1. #108Armata PharmaceuticalsARMP$111.2M
  2. #109HumacyteHUMA$108.3M
  3. #110Outlook TherapeuticsOTLK$107.3M
  4. #111Voyager TherapeuticsVYGR$106.0M
  5. #112Anavex Life SciencesAVXL$102.4M

What if Outlook Therapeutics were worth as much as…

Open the what-if tool →

Gold $28.2T

$115,987.50

Per share 263,189× higher

Bitcoin $1.53T

$6,275.88

Per share 14,241× higher

Apple $5.02T

$20,603.13

Per share 46,751× higher

Or at a round number

$200.0M$500.0M$1.00B$2.00B

Where these numbers come from

Share counts and financials for Outlook Therapeutics are taken from its own SEC filings via EDGAR: public record, not an estimate. Market cap is shares outstanding multiplied by the latest close. Read the methodology.